Lerato Mohapi to HIV Infections
This is a "connection" page, showing publications Lerato Mohapi has written about HIV Infections.
Connection Strength
1,667
-
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. AIDS. 2022 03 01; 36(3):373-382.
Score: 0,218
-
The effect of a maturing antiretroviral program on early mortality for patients with advanced immune-suppression in Soweto, South Africa. PLoS One. 2013; 8(11):e81538.
Score: 0,123
-
STRETCHing delivery of HIV health services. Lancet. 2012 Sep 08; 380(9845):865-7.
Score: 0,112
-
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023 09 18; 77(6):892-900.
Score: 0,061
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
Score: 0,058
-
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing. Antimicrob Agents Chemother. 2022 09 20; 66(9):e0238521.
Score: 0,056
-
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. J Int AIDS Soc. 2022 06; 25(6):e25905.
Score: 0,055
-
Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants. J Acquir Immune Defic Syndr. 2021 05 01; 87(1):720-729.
Score: 0,051
-
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 01; 31(1):17-27.
Score: 0,050
-
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. J Infect Dis. 2020 07 09; 222(Suppl 1):S41-S51.
Score: 0,049
-
HIV research in South Africa: Advancing life. S Afr Med J. 2019 Dec 05; 109(11b):36-40.
Score: 0,047
-
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019 09; 6(9):e588-e600.
Score: 0,046
-
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 03 14; 380(11):1001-1011.
Score: 0,044
-
HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries. Int J Tuberc Lung Dis. 2018 12 01; 22(12):1443-1449.
Score: 0,043
-
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS. 2018 01 28; 32(3):357-361.
Score: 0,041
-
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 01; 4(1):e13-e20.
Score: 0,038
-
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015 Oct 15; 61(8):1322-7.
Score: 0,034
-
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul; 15(7):793-802.
Score: 0,034
-
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS One. 2015; 10(2):e0118228.
Score: 0,034
-
CD4 counts and viral loads of newly diagnosed HIV-infected individuals: implications for treatment as prevention. PLoS One. 2014; 9(3):e90754.
Score: 0,031
-
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013 Jun 15; 381(9883):2091-9.
Score: 0,030
-
Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. J Acquir Immune Defic Syndr. 2013 Mar 01; 62(3):322-328.
Score: 0,029
-
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 2012; 9(6):e1001236.
Score: 0,028
-
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
Score: 0,027
-
The impact of highly active antiretroviral therapy on activities of daily living in HIV-infected adults in South Africa. AIDS Behav. 2011 May; 15(4):823-31.
Score: 0,026
-
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011 Mar 09; 6(3):e17518.
Score: 0,025
-
Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS. 2011 Jan 02; 25(1):87-94.
Score: 0,025
-
Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS. 2010 Nov 13; 24(17):2687-96.
Score: 0,025
-
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
Score: 0,025
-
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS. 2010 Sep 10; 24(14):2263-70.
Score: 0,025
-
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
Score: 0,024
-
Body mass index and risk of tuberculosis and death. AIDS. 2010 Jun 19; 24(10):1501-8.
Score: 0,024
-
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15; 201(6):803-13.
Score: 0,024
-
Role of menstruation in contraceptive choice among HIV-infected women in Soweto, South Africa. Contraception. 2010 Jun; 81(6):547-51.
Score: 0,024
-
Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. S Afr Med J. 2009 Sep; 99(9):653-60.
Score: 0,023
-
A qualitative assessment of decisions affecting contraceptive utilization and fertility intentions among HIV-positive women in Soweto, South Africa. AIDS Behav. 2009 Jun; 13 Suppl 1:47-54.
Score: 0,022
-
Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009 Mar 01; 50(3):327-30.
Score: 0,022
-
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016 Mar 19; 387(10024):1198-209.
Score: 0,009
-
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009 Mar 13; 23(5):631-6.
Score: 0,006